These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21507170)

  • 41. Role of CYP2C19 polymorphisms in patients with endometriosis.
    Cayan F; Ayaz L; Aban M; Dilek S; Gümüş LT
    Gynecol Endocrinol; 2009 Aug; 25(8):530-5. PubMed ID: 19499406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
    Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
    Zandvliet AS; Huitema AD; Copalu W; Yamada Y; Tamura T; Beijnen JH; Schellens JH
    Clin Cancer Res; 2007 May; 13(10):2970-6. PubMed ID: 17504998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse reactions to voriconazole.
    Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
    Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
    Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
    Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
    Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
    Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of voriconazole on the pharmacokinetics of diclofenac.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
    Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
    Burger DM; Schwietert HR; Colbers EP; Becker M
    Br J Clin Pharmacol; 2006 Aug; 62(2):250-2. PubMed ID: 16842404
    [No Abstract]   [Full Text] [Related]  

  • 50. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
    Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Sugimura H; Hishida A; Ishizaki T
    Aliment Pharmacol Ther; 2005 Nov; 22(10):1033-40. PubMed ID: 16268979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.
    Srinivas NR
    Aliment Pharmacol Ther; 2017 Oct; 46(7):706-707. PubMed ID: 28880446
    [No Abstract]   [Full Text] [Related]  

  • 52. Voriconazole-induced periostitis.
    Rossier C; Dunet V; Tissot F; Aubry-Rozier B; Marchetti O; Boubaker A
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):375-6. PubMed ID: 21894545
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
    Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
    Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
    Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.
    Xu RA; Gu EM; Liu TH; Ou-Yang QG; Hu GX; Cai JP
    Infect Drug Resist; 2018; 11():2129-2135. PubMed ID: 30464555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.
    Storelli F; Samer C; Reny JL; Desmeules J; Daali Y
    Clin Pharmacokinet; 2018 Oct; 57(10):1267-1293. PubMed ID: 29667038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated Voriconazole Level Associated With Hallucinations and Suicidal Ideation: A Case Report.
    Jansen JW; Sen SK; Moenster RP
    Open Forum Infect Dis; 2017; 4(1):ofw215. PubMed ID: 28480228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PharmGKB summary: voriconazole pathway, pharmacokinetics.
    Barbarino JM; Owusu Obeng A; Klein TE; Altman RB
    Pharmacogenet Genomics; 2017 May; 27(5):201-209. PubMed ID: 28277330
    [No Abstract]   [Full Text] [Related]  

  • 59. Voriconazole toxicity related to polymorphisms in CYP2C19.
    Suan D; O'Connor K; Booth DR; Liddle C; Stewart GJ
    Intern Med J; 2011 Apr; 41(4):364-5. PubMed ID: 21507170
    [No Abstract]   [Full Text] [Related]  

  • 60. Voriconazole therapeutic drug monitoring: focus on safety.
    Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
    Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.